APC-100, a novel pharmaceutical neuroregeneration therapy for the Alzheimers disease
Joint Event on 3rd International Conference on Food Science & Technology & World Congress on Biotechnology & Medical Microbiology
October 25-26, 2018 | Frankfurt, Germany
University of Central Florida, USA
Posters & Accepted Abstracts : J Biotech and Phyto
One of the primary hurdles of Alzheimer’s disease (AD) therapy is that it requires more then one solution to successfully stop or reverse it since the disease degenerate many different types of cells as compare to the other neurodegenerative diseases. That is why the stem cells could be useful to treat AD since they could produce those different types of cells according to the environments. However, to use stem cells, influences from the pathological environment of AD must be addressed. The AD brain over produces amyloid precursor protein (APP), which then results in amyloid plaques, one of the hallmarks of AD. We found that the pathological level of APP prevents neural stem cells (NSCs) to differentiate into neurons. Our approach is to combine small molecule therapeutics for both modifying the pathological condition AD and increasing endogenous NSCs. With phenserine, a drug reduces APP production, we were able to control the APP to a normal level, which allows NSCs to differentiate into neurons. Then we combined KS-217, a pyro pyrimidine derivative, which pass through the blood brain barrier to increase endogenous NSCs at the significant level, eliminating the need of NSCs transplantation. This combination therapeutic approach (APC-100) has proven effective in improving cognition and increasing neuroregeneration in AD mice model. APC-100 will introduce totally new concept to AD stem cell therapy, which does not require any transplantable cell materials.